RU2017116973A - Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса - Google Patents

Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса Download PDF

Info

Publication number
RU2017116973A
RU2017116973A RU2017116973A RU2017116973A RU2017116973A RU 2017116973 A RU2017116973 A RU 2017116973A RU 2017116973 A RU2017116973 A RU 2017116973A RU 2017116973 A RU2017116973 A RU 2017116973A RU 2017116973 A RU2017116973 A RU 2017116973A
Authority
RU
Russia
Prior art keywords
heart failure
pharmaceutical preparation
mammal
neuregulin
composition
Prior art date
Application number
RU2017116973A
Other languages
English (en)
Russian (ru)
Other versions
RU2017116973A3 (enExample
Inventor
Миндун ЧЖОУ
Original Assignee
Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи Лимитед filed Critical Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи Лимитед
Publication of RU2017116973A publication Critical patent/RU2017116973A/ru
Publication of RU2017116973A3 publication Critical patent/RU2017116973A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2017116973A 2014-10-17 2015-10-08 Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса RU2017116973A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410550212.7 2014-10-17
CN201410550212.7A CN105561298A (zh) 2014-10-17 2014-10-17 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
PCT/CN2015/091459 WO2016058493A1 (zh) 2014-10-17 2015-10-08 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物

Publications (2)

Publication Number Publication Date
RU2017116973A true RU2017116973A (ru) 2018-11-19
RU2017116973A3 RU2017116973A3 (enExample) 2019-05-06

Family

ID=55746124

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017116973A RU2017116973A (ru) 2014-10-17 2015-10-08 Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса

Country Status (10)

Country Link
US (3) US10561709B2 (enExample)
EP (2) EP3207940B1 (enExample)
JP (4) JP2017532343A (enExample)
KR (2) KR102603711B1 (enExample)
CN (3) CN111407882A (enExample)
AU (2) AU2015333335B2 (enExample)
CA (1) CA2963322A1 (enExample)
ES (1) ES2924395T3 (enExample)
RU (1) RU2017116973A (enExample)
WO (1) WO2016058493A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006332340B2 (en) 2005-12-30 2013-09-26 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for improved cardiac function
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
CN109276705B (zh) 2012-10-08 2023-10-20 上海泽生科技开发股份有限公司 治疗糖尿病患者心力衰竭的组份和方法
EP3610905B1 (en) 2013-05-22 2021-03-31 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for treating heart failure
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
EP3774859B1 (en) 2018-04-11 2024-03-13 Salubris Biotherapeutics, Inc. Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof
CN111407881A (zh) * 2019-01-07 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物
AR121035A1 (es) * 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
CN113289002A (zh) * 2020-02-24 2021-08-24 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物
CN116710139A (zh) * 2020-11-12 2023-09-05 安进股份有限公司 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法
CN117797243A (zh) * 2022-09-30 2024-04-02 上海泽生科技开发股份有限公司 神经调节蛋白及其应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001489A1 (en) 1987-08-10 1989-02-23 Commonwealth Scientific And Industrial Research Or Control of angiogenesis and compositions and methods therefor
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US6750196B1 (en) 1995-03-27 2004-06-15 Acorda Therapeutics Methods of treating disorders of the eye
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
CA2278151C (en) 1997-02-10 2010-11-16 Genentech, Inc. Heregulin variants
WO1999018976A1 (en) 1997-10-14 1999-04-22 Cambridge Neuroscience, Inc. Therapeutic methods comprising use of a neuregulin
US6054261A (en) 1998-05-20 2000-04-25 Q-Pharma, Inc. Coenzyme Q10 compositions for organ protection during perfusion
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
CA2400595A1 (en) 2000-02-28 2001-09-07 Decode Genetics Ehf Human schizophrenia gene
MXPA02011656A (es) 2000-05-23 2004-07-30 Cenes Pharmaceuticals Inc Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
AU2001290864A1 (en) 2000-09-12 2002-04-02 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Optimized cardiac contraction through differential phosphorylation of myosin
US6482624B2 (en) 2000-11-14 2002-11-19 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
RU2180843C1 (ru) 2001-02-19 2002-03-27 Новокузнецкий государственный институт усовершенствования врачей Способ профилактики повторного инфаркта миокарда
CN1498656A (zh) 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
WO2004050894A2 (en) 2002-11-27 2004-06-17 Artesian Therapeutics, Inc. Heart failure gene determination and therapeutic screening
EP1631268A2 (en) 2003-05-21 2006-03-08 Board Of Regents The University Of Texas System Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure
CN1715926B (zh) 2004-07-02 2011-08-17 上海泽生科技开发有限公司 神经调节蛋白突变体的应用
CA2583972A1 (en) 2004-10-14 2006-10-19 Adventures Plus Pty Ltd A method for the treatment of gastrointestinal and other disorders with an admixture of vitamins and minerals
US20060160062A1 (en) 2005-01-14 2006-07-20 Young Lindon H Perfusion and/or preservation solution for organs
US20070141548A1 (en) 2005-03-11 2007-06-21 Jorg Kohl Organ transplant solutions and method for transplanting organs
CN100361709C (zh) 2005-08-30 2008-01-16 山东省生物药物研究院 一种对生命活性物质有保护作用的糖类组合
CN1768859A (zh) 2005-10-24 2006-05-10 天津大学 基于醛基的微粒表面多重生物功能因子组装方法
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
AU2006332340B2 (en) 2005-12-30 2013-09-26 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for improved cardiac function
CN101394861A (zh) * 2005-12-30 2009-03-25 上海泽生科技开发有限公司 纽兰格林持续给药能改善心脏功能
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
JP2010517023A (ja) 2007-01-25 2010-05-20 エフ．ホフマン−ラ ロシュ アーゲー 心不全の評価におけるｉｇｆｂｐ−７の使用
CN101310779A (zh) 2007-05-25 2008-11-26 上海泽生科技开发有限公司 包含神经调节蛋白的装置及药物制剂
CN101310766B (zh) 2007-05-25 2014-04-16 上海泽生科技开发有限公司 神经调节蛋白的新用途
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
JP5797112B2 (ja) * 2008-07-17 2015-10-21 アコーダ セラピューティクス インコーポレイテッド 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法
EP2808339B1 (en) 2008-11-28 2017-02-15 Zensun (Shanghai) Science & Technology, Co., Ltd. Neuregulin peptides and their use
US20110229444A1 (en) 2008-11-28 2011-09-22 Zensun (Shanghai) Science & Technology Limited Neuregulin And Cardiac Stem Cells
EP2440236B1 (en) * 2009-06-09 2016-05-04 Zensun (Shanghai) Science and Technology Limited Neuregulin based methods for treating heart failure
ES2748886T3 (es) * 2009-06-09 2020-03-18 Zensun Shanghai Science & Tech Co Ltd Métodos basados en Neuregulina para el tratamiento de la insuficiencia cardíaca
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
JP5890785B2 (ja) 2010-03-10 2016-03-22 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド抗生物質の非経口製剤
WO2011119836A1 (en) * 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
CN108420827A (zh) 2010-07-22 2018-08-21 雷文制药有限公司 包含磁偶极子稳定化溶液的组合物及其用途
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
CN109276705B (zh) 2012-10-08 2023-10-20 上海泽生科技开发股份有限公司 治疗糖尿病患者心力衰竭的组份和方法
US20160129084A1 (en) * 2013-03-06 2016-05-12 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure
EP3610905B1 (en) 2013-05-22 2021-03-31 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for treating heart failure
CN104758300A (zh) 2014-01-02 2015-07-08 上海泽生科技开发有限公司 维生素d及其组合物的抗菌用途
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物

Also Published As

Publication number Publication date
CN108064164A (zh) 2018-05-22
KR102603711B1 (ko) 2023-11-20
RU2017116973A3 (enExample) 2019-05-06
KR20170066440A (ko) 2017-06-14
JP2017532343A (ja) 2017-11-02
JP2020193217A (ja) 2020-12-03
CA2963322A1 (en) 2016-04-21
KR20230159650A (ko) 2023-11-21
AU2015333335A1 (en) 2017-04-20
US20220354928A1 (en) 2022-11-10
CN105561298A (zh) 2016-05-11
WO2016058493A1 (zh) 2016-04-21
EP4112068A1 (en) 2023-01-04
EP3207940A1 (en) 2017-08-23
US20200368317A1 (en) 2020-11-26
JP2024164068A (ja) 2024-11-26
ES2924395T3 (es) 2022-10-06
US10561709B2 (en) 2020-02-18
JP2022153417A (ja) 2022-10-12
AU2021258063B2 (en) 2025-02-27
AU2021258063A1 (en) 2021-11-25
EP3207940A4 (en) 2018-06-06
AU2015333335B2 (en) 2021-08-05
CN111407882A (zh) 2020-07-14
EP3207940B1 (en) 2022-06-01
US20170232068A1 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
JP2017532343A5 (enExample)
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
AR083878A1 (es) Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
ES2682670T3 (es) Lisinas de bacteriófagos de Streptococcus para la detección y tratamiento de bacterias gram positivas
EP4397372A3 (en) Methods of treating lennox-gastaut syndrome using fenfluramine
MY167232A (en) Polypeptides binding to human complement c5
EP4349359A3 (en) Peptide exhibiting wrinkle-improving activity and uses thereof
WO2015187998A3 (en) Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
RU2017113775A (ru) Применение нейрегулина в профилактике, лечении или отсрочке развития желудочковой аритмии и его композиция
WO2011112867A8 (en) The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
WO2016005328A3 (en) IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID ß (Aß) AMINO ACID SEQUENCES AND USES THEREOF
WO2017022962A8 (ko) Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
RU2017128296A (ru) Композиция для лечения бесплодия
JP2018509388A5 (enExample)
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
RU2016108808A (ru) Терапевтическое применение vegf-c и ccbe1
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
CA3010788A1 (en) Methods of administering vasopressors
MX2016011115A (es) Terapia inmunorreguladora contra autoinmunidad en diabetes tipo 1.
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
RU2017126212A (ru) Композиция
WO2015168488A3 (en) Islet amyloid polypeptides with improved solubility
JP2017517561A5 (enExample)
EA201691498A1 (ru) Новая мишень для лечения и профилактики диабета

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200805